The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study

Autor: Val Gebski, Ronald Cw Ma, Rachel O'Connell, Weiping Jia, Andrzej S. Januszewski, Kwok Leung Ong, David R. Sullivan, Kerry-Anne Rye, Anthony C Keech, Russell S. Scott, Alicia J. Jenkins, Aimin Xu, Liang Wu, Liping Li, Huating Li
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Time Factors
Myeloblastin
serine protease
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
Type 2 diabetes
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Fenofibrate
Proteinase 3
Intervention (counseling)
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
Humans
cardiovascular diseases
Aged
Hypolipidemic Agents
Inflammation biomarkers
diabetes
biology
business.industry
Middle Aged
Cardiovascular disease
medicine.disease
Lipids
microvascular disease
proteinase 3
Treatment Outcome
030104 developmental biology
Diabetes Mellitus
Type 2
Neutrophil elastase
biology.protein
Biomarker (medicine)
Female
Original Article
Inflammation Mediators
Leukocyte Elastase
Cardiology and Cardiovascular Medicine
business
neutrophil elastase
Biomarkers
medicine.drug
Zdroj: Diabetes & Vascular Disease Research
ISSN: 1752-8984
1479-1641
Popis: Introduction: Neutrophil elastase (NE) and proteinase 3 (PR3) are novel inflammation biomarkers. We investigated their associations with chronic complications, determinants of biomarker levels and effects of fenofibrate in patients with type 2 diabetes mellitus (T2DM) from Fenofibrate Intervention and Event Lowering in Diabetes study. Methods: Plasma NE and PR3 levels were quantified at baseline ( n = 2000), and relationships with complications over 5-years assessed. Effects of fenofibrate on biomarker levels ( n = 200) were determined at four follow-up visits. Results: Higher waist-to-hip ratio, homocysteine and C-reactive protein and lower apoA-II were determinants of higher NE and PR3 levels. Higher NE levels were associated with on-trial stroke and cardiovascular mortality, and higher PR3 levels with on-trial stroke, but associations were not significant after adjustment for confounding factors. Although higher NE and PR3 levels were associated with baseline total microvascular disease, only NE levels were associated with on-trial neuropathy or amputation. These associations were not significant after adjusting for multiple comparisons. NE and PR3 levels did not change with fenofibrate. Conclusions: In T2DM plasma NE and PR3 levels are associated with vascular risk factors, and total microvascular disease at baseline, but on rigorous analyses were not associated with on-trial complications. Levels were not changed by fenofibrate.
Databáze: OpenAIRE
Externí odkaz: